All In Biotech

Drug Trial Radar · NCT00784147

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

A Phase 2b, Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced Patients Infected With HIV-1(Amended to 24-Weeks)

Last checked: Nov 20, 2026Latest source record: May 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

Aug 2008

Primary completion

Apr 2011

Study completion Apr 2011

Sponsor

Lead sponsor
TaiMed Biologics Inc.Industry
Sponsor type
Industry
First posted
Nov 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigational product, ibalizumab, is a humanized IgG4 monoclonal antibody administered via intravenous infusion at 800 mg every 2 weeks or at 2000 mg every 4 weeks. In addition to study drug, all patients will receive an optimized background regimen (OBR), which is a standard-of-care regimen selected by the investigator prior to randomization that is comprised of 2-4 antiretroviral agents. These agents must have been approved by the local regulatory agency or be available through expanded-access programs for treatment of human immunodeficiency virus (HIV).

Conditions

  • HIV

Interventions

  • IbalizumabDrug

    Ibalizumab 800 mg IV every 2 weeks

  • IbalizumabDrug

    Ibalizumab 2000 mg IV every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Proportion of Patients Achieving Undetectable Viral Loads at Week 24.Time frame: 24 weeks

Locations

30 sites in 2 countries. Site status is shown where the registry gives one.

  • AIDS Health Care Foundation - Research

    Beverly Hills, California

  • Living Hope Clinical Foundation

    Long Beach, California

  • Kaiser Permanente Medical Center

    Los Angeles, California

  • Quest Clinical Research

    San Francisco, California

  • Kaiser Permanente Medical Center Research Unit

    San Francisco, California

  • Kaiser Permanente of Colorado

    Denver, Colorado

  • National Jewish Medical & Research Center

    Denver, Colorado

  • Whitman-Walker Clinic

    Washington D.C., District of Columbia

  • South Florida Clinical Research

    Atlantis, Florida

  • University of Miami, Miller School of Medicine

    Miami, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Associates in Infectious Diseases

    Port Saint Lucie, Florida

  • Treasure Coast Infectious Disease Consultants

    Vero Beach, Florida

  • Triple O Medical Services, Inc.

    West Palm Beach, Florida

  • Northstar Medical Center

    Chicago, Illinois

  • Indiana University School of Medicine - Wishard Memorial Hospital

    Indianapolis, Indiana

  • St. Michael's Medical Center

    Newark, New Jersey

  • AIDS Community Research Initiative of America

    New York, New York

  • The Brody School of Medicine at ECU

    Greenville, North Carolina

  • The Research & Educational Group

    Portland, Oregon

  • Central Texas Clinical Research

    Austin, Texas

  • North Texas Infectious Disease Consultants

    Dallas, Texas

  • Valley AIDS Council

    Harlingen, Texas

  • Therapeutic Concepts

    Houston, Texas

  • University of Texas Health Science Center

    Houston, Texas

  • Nationsmed Clinical Research

    Houston, Texas

  • Dr. Gordon E. Crofoot, MD, PA

    Houston, Texas

  • Research Access Network

    Houston, Texas

  • Clinical Research Puerto Rico

    San Juan, Puerto Rico

  • HOPE Clinical Research

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.